Abstract

Extracellular histones in neutrophil extracellular traps (NETs) or in chromatin from injured tissues are highly pathological, particularly when liberated by DNases. We report the development of small polyanions (SPAs) (~0.9–1.4 kDa) that interact electrostatically with histones, neutralizing their pathological effects. In vitro, SPAs inhibited the cytotoxic, platelet-activating and erythrocyte-damaging effects of histones, mechanistic studies revealing that SPAs block disruption of lipid-bilayers by histones. In vivo, SPAs significantly inhibited sepsis, deep-vein thrombosis, and cardiac and tissue-flap models of ischemia-reperfusion injury (IRI), but appeared to differ in their capacity to neutralize NET-bound versus free histones. Analysis of sera from sepsis and cardiac IRI patients supported these differential findings. Further investigations revealed this effect was likely due to the ability of certain SPAs to displace histones from NETs, thus destabilising the structure. Finally, based on our work, a non-toxic SPA that inhibits both NET-bound and free histone mediated pathologies was identified for clinical development.

Histones, proteins that bind DNA, are toxic for pathogens outside cells but can also cause multi-organ damage as seen in sepsis. Here the authors develop small negatively charged molecules that can be used as histone antidotes, and show that they improve the phenotype in mouse models with histone-related pathologies.

Details

Title
Neutralizing the pathological effects of extracellular histones with small polyanions
Author
Meara Connor H O’ 1   VIAFID ORCID Logo  ; Coupland, Lucy A 1   VIAFID ORCID Logo  ; Kordbacheh Farzaneh 1 ; Quah, Benjamin J, C 1 ; Chang, Chih-Wei 2   VIAFID ORCID Logo  ; Simon Davis David A 1 ; Bezos, Anna 1 ; Browne, Anna M 1   VIAFID ORCID Logo  ; Freeman, Craig 1   VIAFID ORCID Logo  ; Hammill, Dillon J 1 ; Chopra Pradeep 2 ; Pipa Gergely 2 ; Madge, Paul D 2 ; Gallant, Esther 3 ; Segovis Courtney 3 ; Dulhunty, Angela F 3 ; Arnolda, Leonard F 4 ; Mitchell, Imogen 5 ; Khachigian, Levon M 6   VIAFID ORCID Logo  ; Stephens, Ross W 7   VIAFID ORCID Logo  ; von Itzstein Mark 2   VIAFID ORCID Logo  ; Parish, Christopher R 1   VIAFID ORCID Logo 

 The Australian National University, ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477) 
 Griffith University, Institute for Glycomics, Gold Coast, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432) 
 Australian National University, Eccles Institute of Neuroscience, John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477) 
 Illawarra Health and Medical Research Institute, Wollongong, Australia (GRID:grid.1001.0) 
 The Canberra Hospital, Intensive Care Unit, Canberra, Australia (GRID:grid.413314.0) (ISNI:0000 0000 9984 5644) 
 University of New South Wales, Vascular Biology and Translational Research, School of Medical Sciences, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432) 
 The Australian National University, Department of Applied Mathematics, Research School of Physics and Engineering, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2473192760
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.